Oct 24, 2016
Envision Pharma Group attended the CBI Medical Communications and Information Summit in San Francisco, October 27−28
Envision Pharma Group attended the CBI Medical Communications and Information Summit in San Francisco, CA, Oct 27−28, the “go-to” industry event for all Medical Affairs professionals to discuss best practices for the effective communication of scientific information for a global market.
Envision Pharma Group offers a comprehensive range of Medical Affairs services and technology solutions. Of note, Alligent – “The Medical Affairs Agency” built to support the strategic and tactical needs of the medical team through a deep and thorough knowledge of the overall medical strategy – are now part of the Envision Pharma Group.
Please visit our website or contact Mike Kramer for more information on our full range of medical affairs services and for a demonstration of our industry-leading software, including Visiontracker®, Visiontracker HEORTM, MedinfoTM, LibraryTM, Clear®, and Datavision®.
Those working within the Medical Information field may be particularly interested in Medinfo – The complete, purpose-built medical information solution that will change the way your company shares information and gathers insights.
Library – Efficient sharing and multi-faceted searchability of materials across the enterprise. Notifies users of new material for release, expiration of material, and when new content becomes available based on a user’s profile.
Clear – A purpose-built solution to facilitate the compliant, efficient, and appropriate evaluation of all clearance and disclosure requests.
Datavision – The world’s leading publication planning software, developed for the strategic and tactical management, and compliant execution of scientific data dissemination.
Visiontracker – The industry-leading, web-enabled software application to manage all independent investigator trial, medical education, and charity projects.
Visiontracker HEOR – The industry-leading workflow solution to manage your HEOR project portfolio end-to-end.